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Introduction {#s1}
============

Tuberculosis (TB) is a major public health problem in the world that affects approximately nine million people, causing deaths in approximately 1.3 million [@pone.0114225-WHO1], with most of the cases and deaths being in sub-Saharan Africa. TB prevention and control relies on the Directly Observed Treatment, Short-term (DOTS) strategy, which focuses on case notification and successful treatment as a measure of its performance [@pone.0114225-WHO1]. TB differentially affects different segments of the community. Some studies report a higher male to female ratio in TB case notification and lower case fatality rates in men [@pone.0114225-Thorson1]--[@pone.0114225-Diwan1]. Access to treatment, poor socioeconomic status [@pone.0114225-Oxlade1], [@pone.0114225-Boccia1], health service access and use, delays in seeking care and diagnosis [@pone.0114225-Storla1] and poor knowledge about the disease [@pone.0114225-Wang1] all contribute to discrepancies in case notifications. A change in the occurrence of the disease by age structure, reducing the proportion of the disease by gender and urban-rural settings and trends of treatment results are important indicators to assess the effectiveness of TB control programmes [@pone.0114225-WHO1], [@pone.0114225-Gninafon1], [@pone.0114225-Abubakar1].

Ethiopia is one of the high TB burden countries due to the related sickness and death [@pone.0114225-WHO1], [@pone.0114225-Shaweno1] undergoing an accelerated decentralization of DOTS, which improved case notification rate and treatment outcomes [@pone.0114225-Federal1], [@pone.0114225-Yassin1]. Unfortunately, the case detection rate of smear-positive TB (PTB+) using passive finding which misses the less advantaged in the community [@pone.0114225-Yassin2], is below the global target of 70% [@pone.0114225-WHO1], [@pone.0114225-Federal1]. In such settings, an active case finding (ACF) could be useful to improve early case finding and treatment at a reasonable cost in resource-constrained settings [@pone.0114225-Yassin2]--[@pone.0114225-Getahun1]. TB case detection and treatment results vary between different regions of Ethiopia [@pone.0114225-Federal1], which could be influenced by reports based on basic management units (BMU) regardless of their place of residence. In real life, people seek diagnosis and treatment wherever the services are accessible, available and preferred. BMU-based data aggregation includes cases from different administrative areas, and not only from the institutional catchment population. This may result in both an over- and underestimation of CNR to the true population and treatment outcomes for the defined administrative areas.

An analysis of trends and differentials in case notifications and treatment outcomes by place of residence, gender and age distribution may help improve our understanding of the performance of DOTS services and true CNR. Previous reports have focused on trends in TB case detection and treatment outcome by socio-demographic factors and treatment sites [@pone.0114225-Yassin1], [@pone.0114225-Shargie1], [@pone.0114225-Woldeyohannes1]. Nevertheless, these studies lack a further analysis based on the true address of cases, which could provide useful evidence for disease control programs for informed decision making. Therefore, the objective of this study is to assess the trends of TB case notification and treatment outcome based on the patient\'s address over a period of 10 years in the Sidama Zone in southern Ethiopia.

Methods {#s2}
=======

Study Area and Setting {#s2a}
----------------------

This study was conducted in the Sidama Zone (the study area) in southern Ethiopia, which is one of the most densely populated areas in Ethiopia, with a population of over 3.4 million [@pone.0114225-Sidama1], [@pone.0114225-Central1]. Ninety-two percent of the population lives in rural areas, and agriculture is the major livelihood of the community. Administratively, the Sidama Zone is divided into 19 woredas (districts) and two towns. Additionally, there are 524 rural and 39 urban kebeles (the lowest administrative units for approximately 5,000 people or 1,000 households on average).

In recent years, there has been a substantial expansion of primary health-care services in the Zone, mostly in relation to public institutions. The public sector runs two hospitals, 102 health centers, seven non-governmental organization (NGO) clinics and 519 health posts, though private facilities were not engaged in TB care during the study period. In 2003, Ethiopia launched the health extension program, a community-based initiative to improve access to basic primary health-care services including TB, primarily focusing on households [@pone.0114225-Federal2]. Each health post is staffed by two female health extension workers (HEWs) from the local communities, who have been trained for one year, receive salaries from the government and provide promotive, preventive and basic curative health services.

DOTS is decentralized and the DOTS providing health facilities in the study area increased from 65 in 2003 to 114 in 2012. TB and HIV collaborative activities such as HIV screening and treatment have also been carried out, and 95% of districts in the study area had at least one ART center in 2012. Health facilities (health-care services) that provide anti-retroviral treatment increased from one in 2003 to 20 in 2012 [@pone.0114225-Sidama2]. Moreover, in October 2011, the zonal health department started a community-based intervention focusing on active case finding [@pone.0114225-Yassin2] to help improve TB case finding and treatment results.

TB Diagnosis and Treatment {#s2b}
--------------------------

We used the National TB control guidelines of Ethiopia for the diagnosis and treatment of TB cases, for case definition and treatment outcomes [@pone.0114225-Federal3]. Health posts render health education, identify suspects, refer patients to health centers and support treatment through HEWs. Health centers conduct sputum microscopy, treatment and the referral of smear-negative and extra pulmonary cases to hospitals for further management, while hospitals provide diagnosis, treatment and in patient care services [@pone.0114225-Federal2], [@pone.0114225-Federal3].

Case Definition {#s2c}
---------------

[Smear-positive pulmonary TB (PTB+)]{.ul} is diagnosed with at least two positive initial sputum smears for Acid Fast Bacilli (AFB) by direct microscopy, or one positive smear for AFB by direct microscopy and culture positive or one positive smear for AFB by direct microscopy and radiographic abnormalities consistent with active TB as determined by a clinician. The laboratory keeps all positive and negative slides for external quality assurance. Quality assurance is performed regularly at the regional laboratory, and feedback is given to a reporting health facility. A previous study reported a high specificity and good agreement of sputum microscopy between peripheral and reference laboratories [@pone.0114225-Shargie2].

[Smear-negative TB (PTB-)]{.ul}is diagnosed when the patient is presented with symptoms suggestive of TB, has at least three initial smear examinations negative for AFB, no response to antibiotics, repeat smear-negative and radiological abnormalities consistent with pulmonary TB, as well as a clinician\'s decision.

[Extra pulmonary TB (EPTB)]{.ul}is diagnosed by one culture-positive specimen from an extra pulmonary site or histo-pathological evidence from a biopsy, which is based on strong clinical evidence consistent with active EPTB by a clinician\'s decision. However, most health facilities diagnose the disease based on a clinician\'s decision because there are inadequate laboratory facilities for sputum culture or histopathology.

[A short course treatment regimen]{.ul} is given for two phases with first line fixed combination therapy [@pone.0114225-Federal3]. The intensive phase treatment lasts for two months with Ethambutol (E), Isoniazid (H), Rifampicin (R) and Pyrazinamide (Z) followed by a continuous six-month phase with Ethambutol and Isoniazid. Since 2011, the continuation phase has lasted for four months, and uses Isoniazid and Rifampicin.

Data Collection {#s2d}
---------------

The study was conducted from August 2012 to February 2013, and data were collected from all health facilities providing DOTS services from 2003 to 2012. We collected TB unit registers from all health facilities in the districts in the year of treatment.

The variables included were: address of the patient, name of the health facility, age, sex, smear result, TB category, TB classification, intensive phase drug, year of treatment, date of treatment started, last date of treatment and treatment outcome. The treatment results included: treatment completed, cured, defaulted (lost-to-follow up), died, transferred out and unknown [@pone.0114225-WHO1], [@pone.0114225-Federal3]. The address of patients consisted of the actual district and kebele of the patient at the time of diagnosis, and we obtained the code for each district and kebele from the Central Statistical Agency (CSA) of Ethiopia, and linked them to each case in the TB registers.

The data were entered using Microsoft Access by university graduates with experience in data management. They were trained for four days with regard to the formats, variables of interest and data collection, including practical sessions by the principal investigator (PI) and experts from the Sidama Zone Department of Health. Data were double-entered and cross-checked by the PI and experts from the Zone for the number of cases by year, facilities and districts, in addition to the correctness and consistency of the information.

We supervised the data entry for completeness and consistency on a regular basis. In the study area, TB cases are reported by the BMU, irrespective of the patient address. The BMUs are health facilities or institutions that compile and report TB cases registered for treatment to higher administrative levels. Thus, patients coming from neighboring districts or regions are reported as the cases from the reporting BMU, which forms the basis for the computation of the case notification and treatment outcomes. We linked the data from cases registered in districts where the health facility is located, though from neighboring- or other districts within the study area to their actual districts and kebeles, using CSA codes to identify the under- or over reporting of case notifications ([Table 1](#pone-0114225-t001){ref-type="table"}). We also visited neighboring health facilities located outside the study area, checked for cases from the study area that were diagnosed and treated at health facilities in the neighboring areas and included them in the study if they were from the study area. Cases from neighboring region or zones diagnosed and treated in the study area were excluded from analysis, while transferred out- and transferred in cases were checked and correctly linked to their treatment outcomes. Addresses with similar names but from different locations were linked to their correct CSA codes to prevent duplication or underreporting.

10.1371/journal.pone.0114225.t001

###### Differences in cases notified after linking TB cases to their correct address in the Sidama Zone, 2003--2012.

![](pone.0114225.t001){#pone-0114225-t001-1}

  Name of the district    Cases reported by BMU   Corrected to true address   From other districts N (%)[\*](#nt102){ref-type="table-fn"}   To other districts N (%) [\*\*](#nt103){ref-type="table-fn"}   +/−   Difference N (%) [\*\*\*](#nt104){ref-type="table-fn"}
  ---------------------- ----------------------- --------------------------- ------------------------------------------------------------- -------------------------------------------------------------- ----- --------------------------------------------------------
  Aleta chuko                     2,253                     2,663                                      501 (19)                                                        91 (4)                               −                           410 (18)
  Aleta wondo                     1,803                     2,623                                     1,456 (56)                                                      636 (35)                              −                           820 (45)
  Aleta wondo town                1,999                      885                                        85 (10)                                                      1199 (60)                             \+                          1114 (56)
  Arbegona                         650                       721                                       108 (15)                                                        37 (6)                               −                            71(11)
  Aroresa                         1,303                     1,374                                      183 (13)                                                       112 (9)                               −                            71 (5)
  Bensa                           2,933                     2724                                        102 (4)                                                       311 (11)                             \+                           209 (7)
  Bona                             953                      1,004                                      213 (21)                                                       162 (17)                              −                            51(5)
  Boricha                         4,583                     3,624                                       52 (1)                                                       1,011 (22)                            \+                           959 (21)
  Bursa                            638                       978                                       368 (38)                                                        28 (4)                               −                           340 (53)
  Chire                            772                       954                                       211 (22)                                                        29 (4)                               −                           182 (24)
  Dale                            3,446                     3,707                                     1,024 (28)                                                      763 (22)                              −                           261 (8)
  Dara                            1,404                     1,345                                      141 (10)                                                       200 (14)                             \+                            59 (4)
  Gorche                           451                       552                                       104 (19)                                                        3 (1)                                −                           101 (22)
  Hawassa zuriya                  1,036                     1,642                                      636 (39)                                                        30 (3)                               −                           606 (58)
  Hula                            2,593                     1,739                                       22 (1)                                                        876 (34)                             \+                           854 (33)
  Loka Abaya                       697                      1,035                                      368 (36)                                                        30 (4)                               −                           338 (48)
  Malga                            957                       926                                        26 (3)                                                         57 (6)                              \+                            31 (3)
  Shebedino                       2,568                     2,937                                      510 (17)                                                       141 (5)                               −                           369 (14)
  Wondo Genet                     3,059                     3,027                                       23 (1)                                                         55 (2)                              \+                            32 (1)
  Wonsho                           431                       966                                       535 (55)                                                        0 (0)                                −                          535 (124)
  Yirgalem town                   2588                      1,644                                       26 (2)                                                        970 (37)                             \+                           944 (36)
  Neighboring zones                216                       263                                          216                                                           263                                                                47
  Total                          37,333                    37,333                                    6,910 (18.5)                                                   7,004 (18.8)                                                      8,404 (22.6)

A total of 216 cases were cases from the study area, but treated at facilities outside the study area and included in the analysis. A total of 263 cases were excluded from analysis because they were from other districts, but treated in the study area. Therefore, 37,070 (37,333--263) cases from the study area were included in the study.

\*Number of cases from other districts/number of cases corrected to true address.

\*\*Number of cases of other districts/number of cases reported by BMU.

\*\*\*Difference between number of cases reported by BMU and number of cases corrected to BMU.

To ensure the quality of the data, we checked the consistency and correctness of the entered information with the information in the TB registries. All TB unit registries were made available until the preliminary analysis, and during the exploratory analysis we looked for errors and corrected them from the registries. To help ensure the completeness and accuracy of the data, the number of cases and patient information entered in each year and health facility were checked page by page and by the year of treatment with the information in the TB registry. Personal identifiers of TB cases were coded to maintain the confidentiality of the patient information prior to analysis, and all medical records (TB unit registries) were kept in a secure place (patient records or information was anonymized and de-identified prior to analysis).

Statistical Analysis {#s2e}
--------------------

Descriptive statistics of trends of case notification and treatment outcomes over the past 10 years were performed for PTB+, PTB- and ETB cases. We obtained each year\'s population data for the study area from CSA [@pone.0114225-Central1], computed case notification rates using the population for different years as a denominator and notified cases as a numerator. We computed the difference between cases reported by health facilities and corresponding districts, the BMU, after linking cases to the correct address in order to acquire actual case notification rates of the study area and to find any under- or over reporting within the districts. We analyzed trends of case notification by age, gender, urban and rural residence, and looked for the evidence of age shift and trends in case notification, as well as any disparity in the trends of case notification.

Univariate and bivariate analyses were carried out to investigate the difference and association between independent and outcome variables. A logistic regression analysis was used to identify factors associated with treatment success, loss-to-follow up and mortality during treatment and control for confounding. The data were exported from Microsoft Access to SPSS version 19. We used SPSS version 19 and EpiInfo 7 for the data analysis, and P\<0.05 was considered statistically significant.

Ethical Approval {#s2f}
----------------

We obtained ethical clearance from the Regional Health Bureau of southern Ethiopia, in addition to a letter of support from the Sidama Zone Department of Health, to visit and obtain information from all districts and health facilities. We coded personal identifiers of cases and kept medical records in a secure place to help maintain the confidentiality of clinical information of cases prior to analysis.

Results {#s3}
=======

A total of 37,333 cases were reported as being diagnosed and treated from 2003 to 2012 in the Sidama Zone, although 263 cases from the neighboring region or zones were excluded from analysis, thus leaving 37,070 (99.3%) cases for analysis. We identified differences between cases reported by BMU and corrected to the cases\' addresses ([Table 1](#pone-0114225-t001){ref-type="table"}). A total of 6,910 (18.5%) cases were reported by other BMUs, which contributed to under reporting, while 7,004 (18.8%) cases were reported from other districts by the BMUs, which contributed to over reporting. Facilities in urban areas reported a large proportion of cases from neighboring rural areas ([Table 1](#pone-0114225-t001){ref-type="table"}).

Of the 37,070 cases, 16,867 (45.5%) were women and 20,193 (54.5%) were men, yielding a male to female ratio of 1.2∶1. The mean age (SD) for all cases was 29 (15) years, (male = 30 (SD 16) and females = 27 (SD 13) years). Most of the cases, a total of 22,545 (61%), were PTB+, 7,989 (22%) were PTB- and 6,464 (17%) were EPTB. A total of 31,912 (86%) cases were from rural areas, whereas 5,158 (14%) were from urban areas. Lastly, 95% (35,314 cases) were new and 5% (1641) were retreatment cases ([Table 2](#pone-0114225-t002){ref-type="table"}).

10.1371/journal.pone.0114225.t002

###### Characteristics of study subjects in the Sidama Zone, 2003--2012.
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  Characteristics                                       2003 N (%)   2004 N (%)   2005 N (%)   2006 N (%)   2007 N (%)   2008 N (%)   2009 N (%)   2010 N (%)   2011 (N %)   2012 N (%)   Year not mentioned (N)   Total (N)
  ---------------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------------------ -----------
  **All cases**                                         2,341 (6)    2,705 (7)    2,774 (8)    2,523 (7)    3,296 (9)    4,125 (11)    3499 (9)    3,303 (9)    5,643 (15)   6,846 (19)           15(0)             37,070
  **Sex**                                                                                                                                                                                                         
  Male                                                  1,322 (56)   1,489 (55)   1,537 (55)   1,417 (56)   1,798 (55)   2,208 (54)   1,974 (56)   1,880 (57)   2,981 (53)   3,576 (52)             11              20,193
  Female                                                1,019 (44)   1,216 (45)   1,237 (45)   1,105 (44)   1,498 (45)   1,911 (46)   1,525 (44)   1,420 (43)   2,662 (47)   3,270 (48)             4               16,867
  Not mentioned                                             0            0            0            1            0         6 (0.1)         0         3 (0.1)         0            0                  0                 10
  **Residence**                                                                                                                                                                                                   
  Urban                                                  341 (15)     496 (18)     438 (16)     456 (18)     544 (17)     571 (14)     540 (15)     515 (16)     625 (11)     628 (9)               4                5,158
  Rural                                                 2,000 (85)   2,209 (82)   2,336 (84)   2,067 (82)   2,752 (83)   3,554 (86)   2,959 (85)   2,788 (84)   5,018 (89)   6,218 (91)             11              31,912
  **Age category** [\*](#nt105){ref-type="table-fn"}                                                                                                                                                              
  0--14                                                  367 (16)     387 (14)     369 (13)     349 (14)     483 (15)     526 (13)     433 (12)     385 (12)     662 (12)     694 (10)              1                4,656
  15--24                                                 712 (31)     765 (29)     814 (30)     735 (30)     966 (30)    1,150 (28)   1,074 (31)   1,019 (31)   1,580 (28)   1,557 (23)             8               10,380
  25--34                                                 673 (29)     805 (30)     826 (30)     711 (29)     919 (28)    1,213 (30)    970 (28)     944 (29)    1,638 (29)   1,878 (28)             2               10,579
  35--44                                                 278 (12)     352 (13)     353 (13)     308 (13)     417 (13)     540 (13)     435 (13)     398 (12)     781 (14)    1,150 (17)             0                5,012
  45--54                                                 145 (6)      220 (8)      215 (8)      195 (8)      231 (7)      353 (9)      307 (9)      299 (9)      564 (10)     880 (13)              2                3,411
  55--64                                                  81 (4)       97 (4)      101 (4)      104 (4)      130 (4)      181 (4)      154 (4)      148 (4)      253 (4)      428 (6)               1                1,678
  65+                                                     59 (3)       59 (2)       70 (3)       68 (3)       96 (3)      105 (3)       92 (3)       97 (3)      162 (3)      249 (4)               0                1,057
  **TB category**                                                                                                                                                                                                 
  PTB+                                                  1,358 (58)   1,586 (59)   1,574 (57)   1,434 (57)   1,734 (53)   2,502 (61)   2,286 (66)   2,156 (65)   4,056 (72)   3,851 (56)             8               22,545
  PTB-                                                   547 (23)     537 (20)     542 (20)     552 (22)     834 (25)     807 (20)     632 (18)     637 (19)     796 (14)    2,101 (31)             4                7,989
  EPTB                                                   433 (19)     577 (21)     643 (23)     526 (21)     722 (22)     799 (19)     572 (16)     504 (15)     791 (14)     894 (13)              3                6,464
  Not specified                                          3 (0.1)      5 (0.2)      15 (0.5)     9 (0.4)      6 (0.2)      17 (0.4)     9 (0.3)      6 (0.3)         0            0                  0                 70
  **Patient category**                                                                                                                                                                                            
  New                                                   2,252 (96)   2,599 (97)   2,654 (97)   2,426 (96)   3,185 (97)   3,918 (96)   3,294 (94)   3,077 (93)   5,392 (96)   6,503 (95)             14              35,314
  Retreatment                                             87 (4)       94 (4)       80 (3)       95 (4)      107 (3)      176 (4)      187 (6)      223 (7)      248 (4)      343 (5)               1                1,641
  Transfer in                                             1 (0)       12 (0.4)     35 (1.3)      1 (0)       4 (0.1)      29 (0.7)     16 (0.5)      1 (0)       3 (0.1)         0                  0                 102
  Others                                                    1            0            5            1            0            2            2            2            0            0                  0                 13

\*Age was not recorded for 297 (0.8%) cases.

Trends in Case Notification Rates {#s3a}
---------------------------------

The case notification for all forms of TB steadily increased between 2003--2012 ([Figure 1](#pone-0114225-g001){ref-type="fig"}). PTB+ CNR declined from 55 per 10^5^ people in 2003 to 51 per 10^5^ people in 2006 (*X^2^* ~trend~, P = 0.004), while increasing from 58 (95% CI 55.8--61.3) per 10^5^ people in 2007 to 111 (95% CI 107.4--114.4) in 2012. The case notification of PTB+ in rural settings declined to 46 per 10^5^ people in 2006 (*X^2^* ~trend~, P = 0.002), and increased to 110 (95% CI; 106.3--113.5) in 2012. In 2011, the CNR of PTB+ doubled for men and women compared to what it was in 2003 ([Table 3](#pone-0114225-t003){ref-type="table"}). The disparity between men and women in CNR declined from 16 per 10^5^ people in 2003 to 8 per 10^5^ people in 2012, while the male to female (M: F) ratio declined from 1.4∶1 to 1.1∶1. Likewise, the CNR of PTB+ in the 45 year and above age groups rose by nearly fourfold ([Table 3](#pone-0114225-t003){ref-type="table"}).

![Trends of TB case notification rates per 105 people by year and by TB category in the Sidama Zone, 2003--2012.](pone.0114225.g001){#pone-0114225-g001}

10.1371/journal.pone.0114225.t003

###### Trends of smear positive TB case notification rate per 10^5^ people in the Sidama Zone, 2003--2012.

![](pone.0114225.t003){#pone-0114225-t003-3}

  Characteristics     Year of treatment                                                                  
  ------------------ ------------------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Total PTB+ Cases          1,358         1,586   1,574   1,434   1,734   2,502   2,286   2,156   4,056   3,851
  **CNRs**                   55            62      58      51      58      82      73      66      122     111
  **Residence**                                                                                          
  Urban                      121           191     138     141     128     155     173     136     162     126
  Rural                      52            54      54      46      55      78      68      63      121     110
  **Sex**                                                                                                
  Male                       63            68      63      56      63      87      82      74      125     118
  Female                     47            55      54      46      54      76      64      58      118     110
  **Age category**                                                                                       
  0--14                      11            12      11      10      10      14      12      11      22      16
  15--24                     106           110     105     90      106     136     132     120     189     159
  25--34                     132           145     142     117     136     198     164     154     280     254
  35--44                     79            101     92      76      101     131     119     96      218     225
  45--54                     72            105     88      78      78      150     140     121     274     280
  55--64                     70            76      73      67      77      144     122     113     221     225
  65+                        47            49      42      51      48      70      51      77      124     135

Trends in Treatment Outcome {#s3b}
---------------------------

Over a period of 10 years, the treatment outcome under DOTS improved among all forms, and PTB+ cases cured under DOTS decreased from 68% in 2003 to 53% in 2008 (*X^2^* ~trend~, P\<0.001) and increased to 89% (95% CI 87--89.1) in 2012. Moreover, cases of all forms of TB lost-to-follow up declined from 12% to 1% in 2012 (*X^2^* ~trend~, P\<0.001) ([Table 4](#pone-0114225-t004){ref-type="table"}).

10.1371/journal.pone.0114225.t004

###### Trends of treatment outcome among tuberculosis cases in the Sidama Zone, 2003--2012.
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  Treatment outcome                                 2003 N (%)   2004 N (%)   2005 N (%)   2006 N (%)   2007 N (%)   2008 N (%)   2009 N (%)   2010 N (%)   2011 N (%)   2012 N (%)   Total N (%)
  ------------------------------------------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ -------------
  **New cases**                                                                                                                                                                      
  **PTB+**                                                                                                                                                                           
  Completed                                          209 (16)     418 (26)     384 (26)     422 (31)     499 (30)     603 (26)     621 (29)     493 (25)     299 (8)      142 (4)     4,090 (19)
  Cured                                              891 (68)     825 (54)     771 (51)     625 (46)     859 (52)    1,231 (53)    960 (45)     896 (45)    3,231 (84)   3,241 (89)   13,530 (64)
  Lost-to-follow up                                  106 (8)      140 (9)       97 (7)      149 (11)     182 (11)     326 (14)     272 (13)     355 (18)     123 (3)      65 (1.4)     1,802 (9)
  Died                                               69 (5.3)     52 (3.4)      40 (3)      46 (3.4)      52 (3)       50 (2)       62 (3)       42 (2)       85 (2)       72 (2)       570 (3)
  Failure                                            4 (0.3)      1 (0.1)      1 (0.1)         0         4 (0.2)      17 (0.7)     12 (0.6)     4 (0.2)      8 (0.2)      10 (0.3)     61 (0.3)
  Not evaluated[\*](#nt106){ref-type="table-fn"}      24 (2)       83 (6)      210 (14)     122 (9)       68 (4)      112 (5)      190 (9)      197 (10)     111 (3)     125 (3.4)     1,242 (6)
  **PTB-**                                                                                                                                                                           
  Completed                                          367 (70)     362 (71)     376 (72)     417 (78)     659 (82)     614 (78)     445 (73)     379 (64)     683 (90)    1,850 (93)   6,152 (81)
  Lost-to-follow up                                  78 (15)      64 (13)      54 (10)      63 (12)      83 (10)      96 (12)      92 (15)      131 (22)      27 (4)       16 (1)      704 (9.2)
  Died                                               59 (11)      49 (10)       32 (6)       31 (6)       38 (5)       26 (3)       20 (3)       23 (4)       29 (4)       54 (3)       361 (5)
  Failure                                               0            0         1 (0.2)      1 (0.2)         0         2 (0.3)      1 (0.2)      2 (0.3)         0            0          7 (0.1)
  Not evaluated[\*](#nt106){ref-type="table-fn"}      17 (3)       37 (7)      63 (12)       23 (4)       25 (3)       46 (6)       51 (8)      63 (11)       23 (3)       62 (3)       410 (5)
  **EPTB**                                                                                                                                                                           
  Completed                                          324 (76)     453 (80)     512 (82)     420 (81)     593 (83)     653 (83)     430 (77)     364 (75)     709 (92)     796 (91)    5,254 (83)
  Lost-to-follow up                                  78 (18)      65 (12)       48 (8)      60 (12)      74 (10)      93 (12)      74 (13)      67 (14)       23 (3)       11 (1)      593 (9.4)
  Died                                                19 (4)       13 (2)       14 (2)       16 (3)       26 (4)       14 (2)       15 (3)       20 (4)       21 (3)       14 (2)       172 (3)
  Not Evaluated[\*](#nt106){ref-type="table-fn"}     6 (1.4)       32 (6)       51 (8)       23 (4)       19 (3)       26 (3)       38 (7)       37 (8)       20 (3)       58 (7)       310 (5)
  Others                                                0         1 (0.2)         0            0         1 (0.1)      1 (0.1)      4 (0.7)         0            0            0          7 (0.1)
  **All new TB cases**                                                                                                                                                               
  Cured + Completed                                 1,791 (80)   2,059 (79)   2,043 (77)   1,888 (78)   2,611 (82)   3,104 (79)   2,461 (75)   2,135 (69)   4,922 (91)   6,029 (92)   29,043 (82)
  Lost-to-follow up                                  262 (12)     269 (10)     199 (8)      275 (11)     340 (11)     517 (13)     440 (13)     554 (18)     173 (3)       79 (1)      3,108 (9)
  Died                                               148 (7)     114 (4.4)      86 (3)       94 (4)      116 (4)       90 (2)       97 (3)       85 (3)      135 (3)      140 (2)      1,105 (3)
  Treatment failure                                  4 (0.2)      2 (0.1)      2 (0.1)       1 (0)       5 (0.2)      21 (0.5)     17 (0.5)     6 (0.2)      8 (0.1)      10 (0.2)     76 (0.2)
  Not evaluated[\*](#nt106){ref-type="table-fn"}      47 (2)      155 (6)      324 (12)     168 (7)      113 (4)      186 (5)      279 (9)      297 (10)     154 (3)      245 (4)     1,968 (5.6)
  Total                                               2,252        2,599        2,654        2,426        3,185        3,918        3,294        3,077        5,392        6,503        35,300
  **Retreatment cases**                                                                                                                                                              
  Completed                                          34 (39)      38 (40)      33 (41)      49 (52)      48 (45)      65 (37)      66 (35)      78 (35)      53 (21)      146 (43)     610 (37)
  Cured                                              30 (35)      24 (30)      21 (22)      21 (22)      28 (26)      64 (36)      56 (30)      76 (34)      163 (66)     150 (44)     647 (39)
  Lost-to-follow up                                   7 (8)        7 (7)        5 (6)       11 (12)      15 (14)      30 (17)      30 (16)      30 (14)       8 (3)        12 (4)       155 (9)
  Died                                               11 (13)       9 (7)        6 (8)        6 (6)        9 (8)        4 (2)        14 (8)       12 (5)       10 (4)       11 (3)       92 (6)
  Failure                                             1 (1)        1 (1)       1 (1.3)       1 (1)          0         4 (2.3)      1 (0.5)       4 (2)       2 (0.8)      1 (0.3)       16 (1)
  Not evaluated                                       4 (5)        4 (4)       11 (14)       7 (7)        7 (7)        9 (5)       20 (11)      23 (10)       12 (5)       23 (7)       119 (7)
  Total                                                 87           94           80           95          107          176          187          223          248          343          1,640

\*Not evaluated = Transferred out cases + Cases for whom treatment outcome was unknown.

Fourteen new and 1 retreatment cases were excluded because the year of treatment was not mentioned.

One case recorded as treatment failure had no TB classification.

The proportion of cases who died during treatment declined from 11% to 3% for PTB- (*X^2^* ~trend~, P\<0.001), and from 5% to 2% for PTB+ (*X^2^* ~trend~, P\<0.001) ([Figure 2](#pone-0114225-g002){ref-type="fig"} and [Table 4](#pone-0114225-t004){ref-type="table"}). More deaths occurred in PTB- than PTB+ cases (AOR 1.65; 95% CI: 1.44--1.90), and similarly, cases in the age groups above 34 years and children had more deaths compared with the 15-24-year-old age group ([Table 5](#pone-0114225-t005){ref-type="table"}). Additionally, patients older than 65 years were almost four times more likely to die during treatment than young adults (AOR 3.86; CI 95%: 2.94--5.10) ([Table 5](#pone-0114225-t005){ref-type="table"}).

![Trends of mortality among TB cases during treatment in the Sidama Zone, 2003--2012.](pone.0114225.g002){#pone-0114225-g002}

10.1371/journal.pone.0114225.t005

###### Various factors associated with treatment success, loss-to-follow up and mortality among 35,314 new tuberculosis cases in the Sidama Zone, 2003-2012.

![](pone.0114225.t005){#pone-0114225-t005-5}

  (n = 35314)              Treatment success   Lost-to-follow up   Mortality                                                                  
  ----------------------- ------------------- ------------------- ----------- ------ ------------------- --------- ----- -------------------- ---------
  **Sex**                                                                                                                                     
  Female                         83.8                1.00                      8.0          1.00                    2.9          1.00         
  Male                            81           0.86 (0.81--0.91)    \<0.001    9.4    1.15 (1.06--1.24)    0.001    3.4   1.07 (0.94--1.21)     0.298
  **Age group**                                                                                                                               
  0--14                          81.3          0.86 (0.78--0.95)     0.002     10.2   1.2 (1.09--1.40)     0.001     3    1.4 (1.09.6--1.70)    0.007
  15--24                         83.1                1.00                      8.4          1.00                    2.1          1.00         
  25--34                         82.6          0.92 (0.85--0.99)     0.031     8.6    1.1 (0.97--1.90)     0.163    2.8   1.37 (1.14--1.65)    0\. 001
  35--44                         82.7          0.88 (0.8--0.97)      0.009     8.2    1.08 (0.95--1.23)    0.264    3.6   1.78 (1.46--2.21)    \<0.001
  45--54                         82.9          0.87 (0.78--0.97)     0.010     7.8    1.06 (0.91--1.24)    0.431    4.3   2.22 (1.80--2.80)    \<0.001
  55--64                         79.3          0.71 (0.61--0.81)    \<0.001    9.8     1.3 (1.1--1.6)      0.003    6.1    3.1 (2.39--3.96)    \<0.001
  65+                            78.6          0.72 (0.60--0.84)    \<0.001    8.7    1.11 (0.87--1.4)     0.399     8    3.86 (2.94--5.10)    \<0.001
  **Residence**                                                                                                                               
  Urban                          79.6                1.00                      9.1          1.00                    3.5          1.00         
  Rural                          82.7          1.11 (1.03--1.2)      0.010     8.8     1.1 (.97--1.21)     0.143    3.1    0.98 (.82--1.15)     0.703
  **TB classification**                                                                                                                       
  PTB+                           82.7                1.00                      8.5          1.00                    2.7          1.00         
  PTB-                           80.5          0.86 (0.80--0.92)    \<0.001    9.2    1.14 (1.03--1.25)    0.009    4.7   1.65 (1.44--1.90)    \<0.001
  EPTB                           82.9          1.1 (1.02--1.19)      0.016     9.4    1.03 (0.94--1.14)    0.525    2.7   0.95 (0.79--1.13)     0.532
  **Year of treatment**                                                                                                                       
  2003                           79.5                1.00                      11.6         1.00                    6.6          1.00         
  2004                           79.2          0.98 (.85--1.12)      0.74      10.4   0.89 (0.74--1.07)    0.20     4.4   0.66 (0.51--0.85)     0.001
  2005                           77.0          0.85 (0.74--0.97)     0.017     7.5    0.62 (0.51--0.75)   \<0.001   3.2   0.48 (0.37--0.63)    \<0.001
  2006                           77.8          0.91 (0.79--1.05)     0.20      11.3   0.96 (0.80--1.15)    0.656    3.9   0.50 (0.42--0.72)    \<0.001
  2007                           82.0          1.18 (1.03--1.35)     0.02      10.7   0.88 (0.74--1.05)    0.253    3.6   0.53 (0.41--0.68)    \<0.001
  2008                           79.2          0.99 (0.87--1.13)     0.912     13.2   1.14 (0.97--1.34)    0.112    2.3   0.33 (0.26--0.44)    \<0.001
  2009                           74.7          0.75 (0.66--.85)     \<0.001    13.4   1.19 (1.01--1.40)    0.042    2.9   0.44 (0.33--0.57)    \<0.001
  2010                           69.4          0.58 (0.51--0.66)    \<0.001    18.0   1.68 (1.43--1.97)   \<0.001   2.8   0.40 (0.30--0.53)    \<0.001
  2011                           91.3           2.6 (2.3--3.05)     \<0.001    3.2    0.26 (0.21--0.31)   \<0.001   2.5   0.36 (0.29--0.46)    \<0.001
  2012                           92.7           3.3 (2.9--3.8)      \<0.001    1.2    0.09 (0.07--0.12)   \<0.001   2.2   0.26 (0.21--0.34)    \<0.001

Cases from rural areas had a higher treatment success (AOR 1.11; CI 95%: 1.03--1.2) than cases from urban areas, whereas the treatment success was less for PTB- cases (AOR 0.86; CI 95%: 0.80--0.92) and more for EPTB cases (AOR 1.10; CI 95%: 1.02--1.19) compared with PTB+ cases ([Table 5](#pone-0114225-t005){ref-type="table"}). Significant differences were also observed in treatment success, loss-to-follow up and mortality between years of treatment ([Table 5](#pone-0114225-t005){ref-type="table"}), and both men (AOR 1.15; CI 95%: 1.06--1.24) and smear-negative cases also had higher loss-to-follow up rates (AOR 1.14; CI 95%: 1.03--1.25).

Discussion {#s4}
==========

We found an increased case notification rate, improved treatment success and a decline in poor treatment outcomes over the past 10 years. However, we noted varying CNRs and treatment outcomes during the study period, and we also found less urban-rural and gender discrepancies in case notification rates.

Globally, gender inequalities have been reported in TB case notification [@pone.0114225-Thorson1], with the male to female ratios ranging from 1.5∶1 -2.2∶1[@pone.0114225-Diwan1], [@pone.0114225-Balasubramanian1], but in contrast, lower male to female ratios were reported from Asia [@pone.0114225-WHO1], [@pone.0114225-Dogar1]. The male to female ratios in our data were lower than reports from other studies. The decline in male to female ratio and a narrowing gender disparity gap in our data could be attributed to an improved access to TB control services [@pone.0114225-Yassin2] and active case finding interventions [@pone.0114225-Yassin2], [@pone.0114225-Datiko1], while gender differences in case notification could be due to access to health services [@pone.0114225-Borgdorff1], biological-, socio-economic- and cultural factors [@pone.0114225-Balasubramanian1], [@pone.0114225-Connolly1]--[@pone.0114225-Ahsan1], as well as poor knowledge and diagnosis delays [@pone.0114225-Wang1]. Nonetheless, because active case finding have exhibited similar trends for both men and women, we believe that access to health services was the primary reason for improving gender differences.

Furthermore, we found a higher CNR of PTB+ in urban- than in rural settings, which could be explained by adverse conditions such as poor socioeconomic status [@pone.0114225-Muniyandi1], [@pone.0114225-Muniyandi2], overcrowding [@pone.0114225-Boccia1] and a high prevalence of HIV/AIDS [@pone.0114225-Abebe1]. Previous studies from southern Ethiopia reported higher TB and HIV co-infection rates (25--30%) in cases from urban settings [@pone.0114225-Yassin3], [@pone.0114225-Datiko3], and the demographic and health survey of Ethiopia also reported a higher prevalence of HIV in urban- than in rural settings [@pone.0114225-Central2].

We found a steady increase in CNR among younger groups and a more than twofold increase in older groups. However, no age groups showed a decreasing trend in CNR over the past decade. In developed countries, the age shift occurred over a period of years, with TB being common in older age groups due to an aging population and the changing epidemiology of the disease [@pone.0114225-Park1]--[@pone.0114225-Schaaf1]. In developing and high burden countries, the disease is common among younger age groups [@pone.0114225-WHO1], [@pone.0114225-Schaaf1]. The increasing trend in CNR in the 65 year olds in our study was consistent with a study from South Korea, though unlike our finding, the proportion of notified TB cases in South Korea for those under the age of 65 decreased [@pone.0114225-Park1]. This difference could be due to population distribution because the proportion of notified cases over 65 years in Korea was higher than notified cases over 65 years in our study, which could also be because of active case finding interventions in the study area [@pone.0114225-Yassin2], [@pone.0114225-Datiko1]. The increase in CNR among the older age group in our study indicates TB among the old has been under-diagnosed, while the observed increase in CNRs during the study period could be attributed to improved access to- and utilization of TB control services [@pone.0114225-Yassin2], [@pone.0114225-Datiko1]. Hence, the DOTS services and community-based interventions in the study area have an improved access to- and use of TB services, as well as a reduced under-diagnosis of TB among older age groups. Nevertheless, increasing aging is related to increased risk due to a reduced immunity and co-morbidities such as diabetes, malignancies and other factors that increase cases [@pone.0114225-Park1], [@pone.0114225-Schaaf1]. The increased CNR among older age groups in our study should be interpreted with caution because studies on age shift in TB occurrence report an age shift after a long study period usually lasting for decades.

Treatment success was poor in 2008--2010, although a notable improvement was observed in 2011--2012. This improvement could be due to an improved access to TB control services, particularly community-based interventions [@pone.0114225-Yassin2], early diagnosis and treatment of the cases, reduction in lost-to-follow up and a decline in the mortality of patients while on treatment. Similarly, a remarkable decline in lost-to-follow up of cases in 2011--2012 could be explained by community-based interventions, which improved access to- and the use of TB control services. Other possible reasons for a notable reduction in lost-to-follow up could be the drop in the proportion of non-evaluated cases compared to preceding years, the expansion of TB treatment centers and a regimen change of the continuation phase to RH, which lasts four months.

In our study, more men were lost-to-follow up than women, with this finding consistent with other studies [@pone.0114225-Daniel1], [@pone.0114225-Muture1]. PTB- cases were associated with a higher loss-to- follow up, which is consistent with a previous study from southern Ethiopia [@pone.0114225-MunozSellart1]. Conversely, a study from Nigeria reported a higher loss-to- follow up among PTB+ cases [@pone.0114225-Daniel1]; this difference could be due to a longer study period, a larger cohort of TB cases and wider geographic settings in our study.

The proportion of cases who died on treatment declined during the study period; however, unlike other studies, there were no significant differences in mortality by gender and urban-rural settings [@pone.0114225-Feng1]. This could be explained by improved access to, and utilization of TB control services and an improved awareness of the disease. The proportion of cases who died on treatment among the age group of 65 years and above in our data was fourfold compared to younger adults. This finding was in agreement with the study from southern Ethiopia, which reported a higher mortality rate among the elderly [@pone.0114225-MunozSellart1]. This could be due to an increased risk of co-morbidities and delay in diagnosis and treatment among older age groups, which could increase adverse treatment outcomes [@pone.0114225-Schaaf1].

The higher proportion of deaths in PTB- cases than PTB+ and EPTB cases in our data might be due to diagnosis and treatment delays, as well as HIV infection among PTB- cases. Studies reported more PTB- cases among HIV-infected individuals [@pone.0114225-Yassin3], [@pone.0114225-Getahun2], while previous studies from southern Ethiopia also reported a high TB-HIV co-infection, with the rate of HIV infection among PTB- cases being 18--26% [@pone.0114225-Yassin3], [@pone.0114225-Datiko3]. The declining trend in mortality during treatment in our study may be explained in part by ART services because ART reduces deaths in TB cases infected with HIV [@pone.0114225-DosSantos1]. In recent years, there has been an increase in both ART centers and the number of patients starting ART in the study area [@pone.0114225-Sidama2].The number of ART centers in the study area increased from one to 20 during the study period. More deaths were also observed among retreatment cases, which is consistent with other reports [@pone.0114225-Mathew1], [@pone.0114225-Kritski1]. Retreatment cases could be drug resistant TB, repeated infection, a recurrence due to a reduced immunity and other co-morbidities that could increase the risk of death.

In our study, we found variations in cases notified by BMU in relation to place of residence, which might mask the real epidemiology of TB in the community. We noted both over- and underreporting of cases within districts in study area; the over reporting was mainly observed from urban health facilities, with the underreporting occurring at neighboring rural areas. This could be attributed to poor access to health facilities that provide TB services for rural areas in their catchment since people use the closest health facilities regardless of their actual address. If health facilities fail to correctly record and report the actual address of patients, and include or miss cases in the numerator of case notification, it results in an under- or over reporting of cases. On the other hand, people may bypass the closer health facility and use health services further away because of patient preference due to poor service delivery in the nearby health facilities or the distribution of health facilities that did not consider the population distribution and required coverage. This finding is important for the TB control program and district authorities because the over- or underreporting of cases may conceal a true burden of the disease, which may lead to flawed conclusions for targeting interventions and resource allocation. Data aggregation based on the correct address of cases could help solve the problem of over- or under-reporting. Thus, improving the recording of the actual patient address and access to TB control services might solve such discrepancies in actual case notification.

One limitation of our study is that patients with no address could be missed; however, the percentage of patients with a missed address and information was too small to affect the results. PTB- and EPTB could also be over- or underestimated because of poor access to standard diagnosis facilities such as culture and histopathology. Information about HIV status and treatment was not available in the registers; consequently, we could not compare the treatment outcomes based on HIV status and treatment. In addition, our study was not a population-based survey, so cases occurring in the community may remain undiagnosed, and a few may remain unregistered. The strengths of our study were that the study was carried out on a large cohort of TB cases, covering a large geographic area and both urban and rural settings. Lastly, this is the first study from Ethiopia that uses patients\' true home addresses to assess the results of a tuberculosis control program, as previous studies have been based on reports from BMU that did not consider the actual address of cases.

Conclusions {#s5}
===========

We have reported that over the past 10 years, TB case notification rates increased, poor treatment outcomes were reduced, while disparities of the disease burden by gender and place of residence also declined. Understanding the epidemiology of TB in such settings is important for resource planning, monitoring and understanding the burden of the disease in the community. Strategies should therefore be devised to address higher risk groups for poor treatment outcomes.
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